|Bid||2.35 x 100|
|Ask||5.35 x 500|
|Day's Range||5.05 - 5.45|
|52 Week Range||2.10 - 6.50|
|PE Ratio (TTM)||-2.33|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
For aTyr Pharma Inc’s (NASDAQ:LIFE) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. The beta measuresRead More...
ATyr Pharma Inc., whose share price has been falling since it went public in 2015, is getting a $45.8 million lift from a group of investors that include a firm that backed the company while it was private....
On a per-share basis, the San Diego-based company said it had a loss of 51 cents. In the final minutes of trading on Monday, the company's shares hit $3.25. A year ago, they were trading at $3.42. _____ ...
The San Diego-based company said it had a loss of 56 cents per share. In the final minutes of trading on Thursday, the company's shares hit $3.10. A year ago, they were trading at $3.01. _____ This story ...
On a per-share basis, the San Diego-based company said it had a loss of 53 cents. For the year, the company reported a loss of $57.9 million, or $2.44 per share. In the final minutes of trading on Thursday, ...
WASHINGTON (AP) — The Supreme Court on Wednesday sided with California-based Life Technologies Corp. in a patent infringement case that limits the international reach of U.S. patent laws.
Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts ...
CEO and Director of Atyr Pharma Inc (NASDAQ:LIFE) John Mendlein bought 69,000 shares of LIFE on 12/19/2016 at an average price of $2.2 a share.
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
aTyr Pharma shares dropped early on Tuesday after the company announced clinical results from its exploratory trials assessing the safety and potential activity of Resolaris.
Companies receiving Fast Track designation from the FDA can signal positive things for companies like aTyr Pharma and its orphan drugs.
aTyr Pharma watched its shares climb early on Monday after the company announced that its product candidate Resolaris was granted Fast Track designation by the FDA.